These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8960386)

  • 1. Susceptibility of exogenous surfactant to phospholipase A2 degradation.
    Duncan JE; Hatch GM; Belik J
    Can J Physiol Pharmacol; 1996 Aug; 74(8):957-63. PubMed ID: 8960386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants.
    Hall SB; Venkitaraman AR; Whitsett JA; Holm BA; Notter RH
    Am Rev Respir Dis; 1992 Jan; 145(1):24-30. PubMed ID: 1731593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of exosurf (surfactant)-mediated suppression of stimulated human alveolar macrophage cytokine responses.
    Thomassen MJ; Antal JM; Connors MJ; Meeker DP; Wiedemann HP
    Am J Respir Cell Mol Biol; 1994 Apr; 10(4):399-404. PubMed ID: 8136155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Turnover of exogenous artificial surfactant.
    Ashton MR; Postle AD; Hall MA; Austin NC; Smith DE; Normand IC
    Arch Dis Child; 1992 Apr; 67(4 Spec No):383-7. PubMed ID: 1586175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Vermont-Oxford Neonatal Network.
    Pediatrics; 1996 Jan; 97(1):1-6. PubMed ID: 8545199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of in vitro surface properties of clove oil-phospholipid suspensions with those of ALEC, Exosurf and Survanta.
    Banerjee R; Bellare JR
    Pulm Pharmacol Ther; 2001; 14(2):85-91. PubMed ID: 11273788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of human alveolar macrophage inflammatory cytokines by tyloxapol: a component of the synthetic surfactant Exosurf.
    Thomassen MJ; Antal JM; Divis LT; Wiedemann HP
    Clin Immunol Immunopathol; 1995 Nov; 77(2):201-5. PubMed ID: 7586728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of exogenous surfactant on the development of surfactant synthesis in premature rabbit lung.
    Amato M; Petit K; Fiore HH; Doyle CA; Frantz ID; Nielsen HC
    Pediatr Res; 2003 Apr; 53(4):671-8. PubMed ID: 12612208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysis of red blood cells and alveolar epithelial toxicity by therapeutic pulmonary surfactants.
    Findlay RD; Taeusch HW; David-Cu R; Walther FJ
    Pediatr Res; 1995 Jan; 37(1):26-30. PubMed ID: 7700730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bulk shear viscosities of endogenous and exogenous lung surfactants.
    King DM; Wang Z; Palmer HJ; Holm BA; Notter RH
    Am J Physiol Lung Cell Mol Physiol; 2002 Feb; 282(2):L277-84. PubMed ID: 11792632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of surfactant mixtures with reactive oxygen and nitrogen species.
    Cifuentes J; Ruiz-Oronoz J; Myles C; Nieves B; Carlo WA; Matalon S
    J Appl Physiol (1985); 1995 May; 78(5):1800-5. PubMed ID: 7649915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surfactant inhibits cationic liposome-mediated gene transfer.
    Tsan MF; Tsan GL; White JE
    Hum Gene Ther; 1997 May; 8(7):817-25. PubMed ID: 9143907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study.
    Sehgal SS; Ewing CK; Richards T; Taeusch HW
    J Natl Med Assoc; 1994 Jan; 86(1):46-52. PubMed ID: 8151722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of synthetic surfactant Exosurf on gene transfer in mouse lung in vivo.
    Raczka E; Kukowska-Latallo JF; Rymaszewski M; Chen C; Baker JR
    Gene Ther; 1998 Oct; 5(10):1333-9. PubMed ID: 9930338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of synthetic surfactants.
    DeAngelis RL; Findlay JW
    Clin Perinatol; 1993 Dec; 20(4):697-710. PubMed ID: 8131363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of modified natural or synthetic surfactant preparations on growth of bacteria causing infections in the neonatal period.
    Rauprich P; Möller O; Walter G; Herting E; Robertson B
    Clin Diagn Lab Immunol; 2000 Sep; 7(5):817-22. PubMed ID: 10973461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exosurf versus Survanta surfactant preparations: proportional-hazards regression analysis of time to successful extubation and discontinuation of oxygen therapy.
    Arnold C; Adams E; Torres E; Sidebottom R
    J Perinatol; 1996; 16(1):9-14. PubMed ID: 8869533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivation of surfactant in rat lungs.
    Bruni R; Fan BR; David-Cu R; Taeusch HW; Walther FJ
    Pediatr Res; 1996 Feb; 39(2):236-40. PubMed ID: 8825793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of inhaled surfactant on pulmonary deposition and clearance of technetium-99m-DTPA radioaerosol.
    Suga K; Mitra A; Domingues C; Alderson PO
    J Nucl Med; 1998 Mar; 39(3):543-7. PubMed ID: 9529308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a protein-free, synthetic surfactant on survival and pulmonary function in preterm lambs.
    Durand DJ; Clyman RI; Heymann MA; Clements JA; Mauray F; Kitterman J; Ballard P
    J Pediatr; 1985 Nov; 107(5):775-80. PubMed ID: 3840530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.